Background: Donor selection in allogeneic hematopoietic stem cell transplantation (HSCT) has evolved beyond human leukocyte antigen (HLA) compatibility. Advances in transplant platforms and immunogenetics have highlighted the importance of integrating additional donor-related clinical and biological factors. Methods: This Brazilian Society of Bone Marrow Transplantation (SBTMO) consensus was developed through a critical review of the current literatureand expert discussion. It addresses the main variables influencing donor selection beyond HLA matching and provides evidence-based recommendations. Results: Donor age is the most relevant non-HLA factor and should be prioritized whenever possible. Other variables-including cytomegalovirus serostatus, ABO compatibility, donor sex and parity, germline predisposition variants, donor eligibility, and ethical considerations-should be incorporated into an individualized decision-making process. A practical algorithm summarizes the proposed recommendations. Conclusion: Donor selection should integrate HLA compatibility with clinical, biological, and ethical factors to optimize transplant outcomes. This consensus provides a practical framework to support evidence-based donor selection in contemporary allogeneic HSCT.
8 January 2026 in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory condition characterized by uncontrolled immune activation and excessive production of pro-inflammatory cytokines, which may rapidly progress to multiorgan failure. Despite efforts to simplify the diagnosis and treatment of this entity, it remains a major challenge in clinical practice, especially in adults. We report a case of suspected primary HLH in an adult patient with a prolonged history of recurrent inflammatory episodes and a fulminant presentation requiring intensive care support. Despite the absence of identifiable genetic mutations, the clinical course was highly suggestive of an underlying primary immune dysregulation. The patient achieved remission with HLH-2004–based therapy and subsequently underwent haploidentical hematopoietic stem cell transplantation (HSCT) due to high risk of recurrence. Seven months after transplantation, she remains in complete remission with full donor chimerism and only mild chronic graft-versus-host disease. This case highlights the diagnostic complexity of adult HLH, the limitations of genetic testing, and supports early consideration of HSCT in selected high-risk patients.
12 June 2026 in Clinical and Translational Science
Tacrolimus pharmacokinetics shows wide interindividual variability after allogeneic hematopoietic cell transplantation (HCT), potentially influencing both effectiveness and toxicity. The concentration‐to‐dose (C/D) ratio has been proposed as a simple surrogate marker of tacrolimus metabolism, enabling patient stratification into fast or slow metabolizers. In this retrospective single‐center study, we evaluated the clinical applicability of the C/D ratio in 71 HCT recipients treated between 2014 and 2023. Fast metabolizers (< 420 ng/mL·1/mg/kg) required higher tacrolimus doses and exhibited lower trough concentrations compared with slow metabolizers (≥ 420). Slow metabolizers had a higher risk of moderate‐to‐severe acute kidney injury (AKI) within 21 days after starting tacrolimus (HR 3.72; 95% CI 1.19–11.61; p = 0.024). In contrast, fast metabolizers showed a trend toward increased incidence of acute graft‐versus‐host disease (aGVHD) (HR 1.91; 95% CI 0.93–3.92) and an almost universal need for dose escalation (96.8%). Tacrolimus metabolism exerts opposing effects on renal safety and immunosuppressive effectiveness, with faster clearance predisposing to immune activation and slower clearance to early AKI. The C/D ratio provides an early pharmacokinetic snapshot capable of anticipating individual exposure patterns and may serve as a practical tool to guide proactive dosing and optimize the balance between effectiveness and safety in HCT recipients.